Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.

Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. Eur J Clin Pharmacol. 2013 Apr; 69(4):813-23.

View in: PubMed

subject areas

Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Benzamides
Biological Availability
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Resistance, Neoplasm
Female
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Male
Middle Aged
Models, Biological
Piperazines
Pyrimidines
Young Adult

authors with profiles

HAGOP M KANTARJIAN